13 results on '"Ching-Chih Lin"'
Search Results
2. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
- Author
-
Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, and Ming‐Lung Yu
- Subjects
efficacy ,hepatocellular carcinoma ,regorafenib ,sorafenib ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. Methods We analyzed the survival, best overall response, predictors of treatment outcomes, and safety for uHCC patients who had tumor progression on sorafenib therapy and received regorafenib as salvage therapy between March 2018 and November 2020. Results Eighty‐six patients with uHCC were enrolled (median age, 66.5 years; 76.7% male). The median regorafenib treatment duration was 4.0 months (95% confidence interval [CI], 3.6–4.6). The most frequently reported adverse events were hand‐foot skin reaction (44.2%), diarrhea (36.0%), and fatigue (29.1%). No unpredictable toxicity was observed during treatment. The median overall survival (OS) with regorafenib was 12.4 months (95% CI, 7.8–17.0) and the median progression‐free survival (PFS) was 4.2 months (95% CI, 3.7–4.7). Of 82 patients with regorafenib responses assessable, 4 patients (4.9%) achieved a partial response, and 33 (40.2%) had stable disease, leading to a disease control rate (DCR) of 45.1% (n = 37). Patients possessing baseline AFP 10% reduction at 4 weeks or >20% reduction at 8 weeks after regorafenib administration) exhibited comparable treatment outcomes to those with baseline AFP
- Published
- 2022
- Full Text
- View/download PDF
3. Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma
- Author
-
Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, and Ming-Lung Yu
- Subjects
receptors, somatotropin ,carcinoma, hepatocellular ,hepacivirus ,recurrence ,prognosis ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background/Aims Growth hormone (GH) is the main regulator of somatic growth, metabolism, and gender dimorphism in the liver. GH receptor (GHR) signaling in cancer is derived from a large body of evidence, although the GHR signaling pathway involved in the prognosis of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related HCC, remains unclear. We aimed to explore the expression of GHR and analyze its association with clinicopathologic features and prognosis of patients with chronic hepatitis C and HCC. Methods The expression of GHR mRNA was investigated by quantitative real-time polymerase chain reaction in paired tumors and adjacent non-tumorous (ANT) liver tissues of 200 patients with chronic hepatitis C and HCC. Western blotting and immunofluorescence assays using the HCV-infected Huh7.5.1 cell model was performed. Results GHR mRNA was significantly lower in HCV-HCC tissues than in corresponding ANT liver tissues. GHR mRNA and protein levels also decreased in the HCV-infected Huh7.5.1 cell model. Notably, lower GHR expression was associated with age of >60 years (P=0.0111) and worse clinicopathologic characteristics, including alpha-fetoprotein >100 ng/mL (P=0.0403), cirrhosis (P=0.0075), vascular invasion (P=0.0052), pathological stage II–IV (P=0.0002), and albumin ≤4.0 g/dL (P=0.0055), which were linked with poor prognosis of HCC. Most importantly, the high incidence of recurrence and poor survival rates in patients with a low ratio of tumor/ANT GHR (≤0.1) were observed, indicating that low expression levels of GHR had great risk for development of HCC in patients with chronic hepatitis C. Conclusions Our study demonstrates a significant down-regulation of GHR expression as a new unfavorable independent prognostic factor in patients with chronic hepatitis C and HCC.
- Published
- 2021
- Full Text
- View/download PDF
4. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
- Author
-
Ming-Ying Lu, Chun-Ting Chen, Yu-Lueng Shih, Pei-Chien Tsai, Meng-Hsuan Hsieh, Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Shu-Chi Wang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu, and Wen-Yu Chang
- Subjects
Medicine ,Science - Abstract
Abstract The spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67.0%) of 1697 prisoners. 89.2% of participants were IDUs and none had HIV infection. The prevalence of HBsAg, anti-HCV, dual HBsAg/anti-HCV, HBsAg/anti-HDV, and triple HBsAg/anti-HCV/anti-HDV was 13.6%, 34.8%, 4.9%, 3.4%, and 2.8%, respectively. HBV viremia rate was significantly lower in HBV/HCV-coinfected than HBV mono-infected subjects (66.1% versus 89.9%, adjusted odds ratio/95% confidence intervals [aOR/CI] = 0.27/0.10–0.73). 47.5% anti-HCV-seropositive subjects (n = 396) were non-viremic, including 23.2% subjects were antivirals-induced. The predominant HCV genotypes were genotype 6(40.9%), 1a(24.0%) and 3(11.1%). HBsAg seropositivity was negatively correlated with HCV viremia among the treatment naïve HCV subjects (44.7% versus 72.4%, aOR/CI = 0.27/0.13–0.58). Anti-HCV seropositivity significantly increased the risk of anti-HDV-seropositivity among HBsAg carriers (57.1% versus 7.1%, aOR/CI = 15.73/6.04–40.96). In conclusion, IUDs remain as reservoirs for multiple hepatitis viruses infection among HIV-uninfected prisoners in Taiwan. HCV infection increased the risk of HDV infection but suppressed HBV replication in HBsAg carriers. An effective strategy is mandatory to control the epidemic in this high-risk group.
- Published
- 2021
- Full Text
- View/download PDF
5. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
- Author
-
Tyng-Yuan Jang, Yu-Ju Wei, Ta-Wei Liu, Ming-Lun Yeh, Shu-Fen Liu, Cheng-Ting Hsu, Po-Yao Hsu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching-I. Huang, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, and Ming-Lung Yu
- Subjects
Medicine ,Science - Abstract
Abstract Hepatitis D virus (HDV) infection increases the risk of hepatocellular carcinoma (HCC) in the natural course of chronic hepatitis B (CHB) patients. Its role in patients treated with nucleotide/nucleoside analogues (NAs) is unclear. We aimed to study the role of hepatitis D in the development of HCC in CHB patients treated with NAs. Altogether, 1349 CHB patients treated with NAs were tested for anti-HDV antibody and RNA. The incidence and risk factors of HCC development were analyzed. Rates of anti-HDV and HDV RNA positivity were 2.3% and 1.0%, respectively. The annual incidence of HCC was 1.4 per 100 person-years after a follow-up period of over 5409.5 person-years. The strongest factor association with HCC development was liver cirrhosis (hazard ratio [HR]/95% confidence interval [CI] 9.98/5.11–19.46, P 50 years old (HR/CI 3.64/2.03–6.54, P
- Published
- 2021
- Full Text
- View/download PDF
6. Metabolomic Analysis Demonstrates the Impacts of Polyketide Synthases PKS14 and PKS15 on the Production of Beauvericins, Bassianolide, Enniatin A, and Ferricrocin in Entomopathogen Beauveria bassiana
- Author
-
Wachiraporn Toopaang, Kullyanee Panyawicha, Chettida Srisuksam, Wei-Chen Hsu, Ching-Chih Lin, Morakot Tanticharoen, Yu-Liang Yang, and Alongkorn Amnuaykanjanasin
- Subjects
Beauveria bassiana ,polyketide synthase ,nonribosomal peptides ,GNPS ,molecular networking ,Microbiology ,QR1-502 - Abstract
Beauveria bassiana is a globally distributed entomopathogenic fungus that produces various secondary metabolites to support its pathogenesis in insects. Two polyketide synthase genes, pks14 and pks15, are highly conserved in entomopathogenic fungi and are important for insect virulence. However, understanding of their mechanisms in insect pathogenicity is still limited. Here, we overexpressed these two genes in B. bassiana and compared the metabolite profiles of pks14 and pks15 overexpression strains to those of their respective knockout strains in culture and in vivo using tandem liquid chromatography-mass spectrometry (LC-MS/MS) with Global Natural Products Social Molecular Networking (GNPS). The pks14 and pks15 clusters exhibited crosstalk with biosynthetic clusters encoding insect-virulent metabolites, including beauvericins, bassianolide, enniatin A, and the intracellular siderophore ferricrocin under certain conditions. These secondary metabolites were upregulated in the pks14-overexpressing strain in culture and the pks15-overexpressing strain in vivo. These data suggest that pks14 and pks15, their proteins or their cluster components might be directly or indirectly associated with key pathways in insect pathogenesis of B. bassiana, particularly those related to secondary metabolism. Information about interactions between the polyketide clusters and other biosynthetic clusters improves scientific understanding about crosstalk among biosynthetic pathways and mechanisms of pathogenesis.
- Published
- 2023
- Full Text
- View/download PDF
7. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
- Author
-
Tyng-Yuan Jang, Yu-Ju Wei, Ming-Lun Yeh, Shu-Fen Liu, Cheng-Ting Hsu, Po-Yao Hsu, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Meng-Hsuan Hsieh, Yu-Min Ko, Yi-Shan Tsai, Kuan-Yu Chen, Ching-Chih Lin, Pei-Chien Tsai, Shu-Chi Wang, Ching-I. Huang, Zu-Yau Lin, Shinn-Cherng Chen, Wan-Long Chuang, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, and Ming-Lung Yu
- Subjects
ALT normalization ,HDV ,NAs ,HBV ,Medicine (General) ,R5-920 - Abstract
Background: The biochemical response is a crucial indicator of prognosis in chronic hepatitis B (CHB) patients treated with nucleotide/nucleoside analogues (NAs). The impact of hepatitis D virus (HDV) infection on alanine aminotransferase normalization is elusive. Methods: The longitudinal study recruited 1185 CHB patients who received NAs. These patients were tested for anti-HDV antibody and HDV RNA at the initiation of anti-hepatitis B virus (HBV) therapy and annually for patients who were HDV-seropositive. ALT levels were examined at the first and second year of anti-HBV therapy. ALT abnormality was defined as ALT levels above 40 IU/mL in both male and female, and the risk factors associated with ALT abnormality were analysed. Results: Rates of seropositivity for anti-HDV and HDV RNA were 2.0% and 0.8% among 1185 NA-treated CHB patients, respectively. The strongest factor associated with ALT abnormality (>40 IU/mL) after first year treatment with NAs was HDV RNA seropositivity at year 1 (odds ratio [OR]/95% confidence interval [CI]: 31.44/3.49–283.56, P = 0.002), followed by liver cirrhosis (2.18/1.51–3.15, P
- Published
- 2021
- Full Text
- View/download PDF
8. Text-Mining and Digital Humanities Analysis of 'Eye-Opening' Consecration Ritual of Contemporary Yanling Daoist Altar of Tainan
- Author
-
Ching-Chih Lin
- Subjects
digital humanities ,text-mining ,information visualization ,gis (geographic information system) ,social network analysis ,Bibliography. Library science. Information resources - Abstract
This article uses Digital Humanities methods and technologies, Text mining and GIS (geographic information system) to explore the ritual texts of the Deity “Eye-Opening” Consecration Ritual of Daoist Wu Zhengxian at the Yanling Daoist Altar in Tainan. The author uses the Python data extraction technology to extract the information of deities, temples, and believers contained in the consecration ritual texts, and then uses GIS time-space analysis and social network analysis to examine the rituals of the Yanling Daoist altar. The article demonstrates the visualization of the spatial distribution of the consecration rituals of the Yanling Daoist Altar. In addition, it also illustrates the network relationship between the deities and the ritual locations, mostly temples. This article aims to show how the use of digital humanities technologies and tools can assist humanities research. The proper use of information technology can quickly and massively process patterned documents (such as Daoist ritual texts), extract key data content, and then use GIS spatial and network analysis to explore the spatial significance and network relationship behind the ritual texts. The author tries to make use of the “distant reading” of digital humanities and proposes new research questions for future studies combined with the “close reading” of traditional research approaches.
- Published
- 2020
- Full Text
- View/download PDF
9. Deep Learning Applied to Defect Detection in Powder Spreading Process of Magnetic Material Additive Manufacturing
- Author
-
Hsin-Yu Chen, Ching-Chih Lin, Ming-Huwi Horng, Lien-Kai Chang, Jian-Han Hsu, Tsung-Wei Chang, Jhih-Chen Hung, Rong-Mao Lee, and Mi-Ching Tsai
- Subjects
convolution neural network ,metal additive manufacturing ,powder-spreading defect ,selective laser melting ,Technology ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Microscopy ,QH201-278.5 ,Descriptive and experimental mechanics ,QC120-168.85 - Abstract
Due to its advantages of high customization and rapid production, metal laser melting manufacturing (MAM) has been widely applied in the medical industry, manufacturing, aerospace and boutique industries in recent years. However, defects during the selective laser melting (SLM) manufacturing process can result from thermal stress or hardware failure during the selective laser melting (SLM) manufacturing process. To improve the product’s quality, the use of defect detection during manufacturing is necessary. This study uses the process images recorded by powder bed fusion equipment to develop a detection method, which is based on the convolutional neural network. This uses three powder-spreading defect types: powder uneven, powder uncovered and recoater scratches. This study uses a two-stage convolutional neural network (CNN) model to finish the detection and segmentation of defects. The first stage uses the EfficientNet B7 to classify the images with/without defects, and then to locate the defects by evaluating three different instance segmentation networks in second stage. Experimental results show that the accuracy and Dice measurement of Mask-R-CNN network with ResNet 152 backbone can reach 0.9272 and 0.9438. The computational time of an image only takes approximately 0.2197 sec. The used CNN model meets the requirements of the early detected defects, regarding the SLM manufacturing process.
- Published
- 2022
- Full Text
- View/download PDF
10. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort
- Author
-
Ta-Wei Liu, Pei-Chien Tsai, Ching-I Huang, Yi-Shan Tsai, Shu-Chi Wang, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Nai-Jen Hou, Chung-Feng Huang, Ming-Lun Yeh, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, and Ming-Lung Yu
- Subjects
chronic hepatitis C ,cost-effectiveness analysis ,pegylated interferon ,ribavirin ,treatment-experienced ,Medicine (General) ,R5-920 - Abstract
Pegylated interferon (PegIFN) plus ribavirin (RBV) combination therapy has been the standard of care since 2002. Although a better viral response has been achieved among chronic hepatitis C (CHC) patients in Taiwan, approximately 25% of hepatitis C virus (HCV) genotype 1 (G1) patients and 15% of G2 patients failed to achieve a sustained virological response (SVR) at the first therapy. The actual cost-effectiveness of the retreatment remains elusive. The present study conducted a real-world cost-effectiveness analysis of a large cohort among different pre-specified subgroups of treatment-experienced CHC patients. Methods: A total of 117 patients with CHC who failed to achieve SVR at the first IFN-based therapy and received a second IFN-based therapy were enrolled. The inpatient and outpatient costs were acquired from National Health Insurance Research Database of Taiwan. The related medical care costs per treatment and per SVR were calculated. Results: We demonstrated that the average cost per SVR achieved was $13,722 in treatment-experienced CHC patients. Especially, patients with HCV G1 infection, baseline viral loads > 400,000 IU/mL, advanced hepatic fibrosis, not achieving a rapid viral response at week 4 or complete early viral response at week 12, had poorer cost-effectiveness for PegIFN/RBV retherapy, ranging from around $15,520 to as high as $72,546 per SVR achieved. Conclusion: In the current study, we explored the real-world cost-effectiveness data of PegIFN/RBV for different subgroups of treatment-experienced HCV patients. These findings provide information for policy-makers for making decisions on treatment strategies of costly direct-acting antiviral agents for retreating CHC patients.
- Published
- 2018
- Full Text
- View/download PDF
11. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
- Author
-
Chung-Feng Huang, Cing-Yi Huang, Ming-Lun Yeh, Shu-Chi Wang, Kuan-Yu Chen, Yu-Min Ko, Ching-Chih Lin, Yi-Shan Tsai, Pei-Chien Tsai, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, and Ming-Lung Yu
- Subjects
HCC ,SVR ,SNP ,MICA ,PNPLA3 ,IL-28 ,EGF ,sMICA ,Treatment ,Medicine ,Medicine (General) ,R5-920 - Abstract
Background/aims: The genome-wide association study has shown that MHC class I chain-related A (MICA) genetic variants were associated with hepatitis C virus (HCC) related hepatocellular carcinoma. The impact of the genetic variants and its serum levels on post-treatment cohort is elusive. Methods: MICA rs2596542 genotype and serum MICA (sMICA) levels were evaluated in 705 patients receiving antiviral therapy. Results: Fifty-eight (8·2%) patients developed HCC, with a median follow-up period of 48·2 months (range: 6–129 months). The MICA A allele was associated with a significantly increased risk of HCC development in cirrhotic non-SVR patients but not in patients of non-cirrhotic and/or with SVR. For cirrhotic non-SVR patients, high sMICA levels (HR/CI: 5·93/1·86–26.38·61, P = 0·002) and the MICA rs2596542 A allele (HR/CI: 4·37/1·52–12·07, P = 0·002) were independently associated with HCC development. The risk A allele or GG genotype with sMICA > 175 ng/mL provided the best accuracy (79%) and a negative predictive value of 100% in predicting HCC. Conclusions: Cirrhotic patients who carry MICA risk alleles and those without risk alleles but with high sMICA levels possessed the highest risk of HCC development once they failed antiviral therapy.
- Published
- 2017
- Full Text
- View/download PDF
12. Corrigendum to 'Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment' [EBioMedicine 15 (2017) 81–89]
- Author
-
Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Shu-Chi Wang, Kuan-Yu Chen, Yu-Min Ko, Ching-Chih Lin, Yi-Shan Tsai, Pei-Chien Tsai, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, and Ming-Lung Yu
- Subjects
Medicine ,Medicine (General) ,R5-920 - Published
- 2017
- Full Text
- View/download PDF
13. GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress.
- Author
-
Chia-Hua Chou, Ching-Chih Lin, Ming-Chang Yang, Chih-Chang Wei, Huei-De Liao, Run-Chin Lin, Wen-Yu Tu, Tsung-Chieh Kao, Ching-Mei Hsu, Jiin-Tsuey Cheng, An-Kuo Chou, Chu-I Lee, Joon-Khim Loh, Shen-Long Howng, and Yi-Ren Hong
- Subjects
Medicine ,Science - Abstract
Multiple phosphorylation sites of Drp1 have been characterized for their functional importance. However, the functional consequence of GSK3beta-mediated phosphorylation of Drp1 remains unclear. In this report, we pinpointed 11 Serine/Threonine sites spanning from residue 634~736 of the GED domain and robustly confirmed Drp1 Ser693 as a novel GSK3beta phosphorylation site. Our results suggest that GSK3beta-mediated phosphorylation at Ser693 does cause a dramatic decrease of GTPase activity; in contrast, GSK3beta-mediated phosphorylation at Ser693 appears not to affect Drp1 inter-/intra-molecular interactions. After identifying Ser693 as a GSK3beta phosphorylation site, we also determined that K679 is crucial for GSK3beta-binding, which strongly suggests that Drp1 is a novel substrate for GSK3beta. Thereafter, we found that overexpressed S693D, but not S693A mutant, caused an elongated mitochondrial morphology which is similar to that of K38A, S637D and K679A mutants. Interestedly, using H89 and LiCl to inhibit PKA and GSK3beta signaling, respectively, it appears that a portion of the elongated mitochondria switched to a fragmented phenotype. In investigating the biofunctionality of phosphorylation sites within the GED domain, cells overexpressing Drp1 S693D and S637D, but not S693A, showed an acquired resistance to H(2)O(2)-induced mitochondrial fragmentation and ensuing apoptosis, which affected cytochrome c, capase-3, -7, and PARP, but not LC3B, Atg-5, Beclin-1 and Bcl2 expressions. These results also showed that the S693D group is more effective in protecting both non-neuronal and neuronal cells from apoptotic death than the S637D group. Altogether, our data suggest that GSK3beta-mediated phosphorylation at Ser693 of Drp1 may be associated with mitochondrial elongation via down-regulating apoptosis, but not autophagy upon H(2)O(2) insult.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.